STING1 and neoplasm: Some approaches explored in NSCLC include targeting the triggering receptor expressed on myeloid cells 2 (TREM2) receptor or activating the cGAS-STING pathway in tumor cells, both of which lead to increased NK cell infiltration [31, 32].